BPC 157 Vascular Study: Nitric Oxide Research

A newly published study in the Journal of Clinical Medicine offers some of the first mechanistic evidence that the peptide BPC 157 may influence vascular tone in human arterial tissue — a meaningful step forward from the animal and cell-based data that has largely defined this field to date. The findings, published in May 2026, suggest that BPC 157 may promote relaxation of blood vessel walls through a pathway involving nitric oxide (NO), a molecule the body uses naturally to regulate blood flow and vascular health.

What This Study Found

Researchers at the study's institution examined the effects of BPC 157 on segments of the human internal mammary artery (IMA) — a vessel commonly harvested during coronary artery bypass graft (CABG) surgery. Using residual IMA tissue collected from 12 patients undergoing elective CABG procedures, the team constructed both endothelium-intact rings (with the inner vessel lining preserved) and endothelium-denuded rings (with that lining removed). This design allowed them to isolate the contribution of the endothelium — the thin layer of cells lining blood vessels that is critical to nitric oxide production.

Each vessel ring was first contracted using phenylephrine, a standard pharmacological agent used to simulate vasoconstriction. The researchers then applied cumulative doses of BPC 157 ranging from 0.01 to 1 mg/mL to observe how the peptide affected that contracted state.

The results showed that BPC 157 produced a concentration-dependent reduction in contraction in both endothelium-intact and endothelium-denuded vessel rings. However, the relaxation response was significantly greater in rings where the endothelium was kept intact (p < 0.05), suggesting the endothelium plays an important amplifying role in BPC 157's vascular activity.

To determine whether nitric oxide signaling was responsible, the researchers pre-treated a subset of rings with L-NAME (Nω-nitro-L-arginine methyl ester), a well-established inhibitor of nitric oxide synthase (NOS) — the enzyme responsible for producing NO in the body. When NOS was blocked, L-NAME increased contractile responsiveness in intact rings, and the vasorelaxant effect of BPC 157 was significantly attenuated. Critically, the difference in response between endothelium-intact and endothelium-denuded rings largely disappeared under NOS inhibition, pointing to endothelium-derived NO as the primary mediator of BPC 157's enhanced efficacy in intact vessels.

Emax (maximum relaxation response) analysis confirmed that endothelial integrity markedly enhanced the peak vasorelaxant effect of BPC 157. Yet even after NOS inhibition, some degree of vasorelaxation persisted, indicating that additional, endothelium-independent mechanisms may also be at play — an area the study's authors note warrants further investigation.

The authors concluded that BPC 157 induces concentration-dependent vasorelaxation in human arterial tissue, predominantly through an endothelium-dependent nitric oxide pathway, while acknowledging that further molecular and in vivo studies are required to clarify clinical relevance (Yildirim et al., 2026).

Clinical Significance

The significance of this study lies not just in what BPC 157 did, but where it did it. Prior research into BPC 157's vasodilatory properties has been conducted primarily in animal models, leaving a meaningful gap in the translational literature. This study's use of living human arterial tissue — even as an ex vivo preparation — represents a more direct line of evidence than preclinical models alone can provide.

Nitric oxide is one of the most important signaling molecules in cardiovascular physiology. It helps blood vessels relax and dilate, reduces the tendency of platelets to clump together, and plays a protective role against endothelial dysfunction — a condition closely linked to atherosclerosis, hypertension, and broader cardiovascular disease risk. The study suggests that BPC 157 may engage this well-established vasoprotective pathway in human tissue, which is a finding of potential interest to researchers working on vascular health, surgical recovery, and endothelial function.

It is important to note, however, that this was an ex vivo study — meaning the experiments were conducted on tissue removed from the body, not in living patients. The results cannot yet be extrapolated directly to clinical outcomes without further in vivo and controlled human trial data. The study's authors are explicit about this limitation, and the Peptide Association underscores this point: the findings are mechanistically interesting but represent an early step on the path toward clinical understanding.

Current Access and Compliance Context

BPC 157 is a synthetic peptide derived from a protein found in human gastric juice. It is not currently approved by the U.S. Food and Drug Administration (FDA) as a drug for any indication and is not available as a licensed pharmaceutical in most countries. In the United States, it has historically been available through compounding pharmacies as a research compound; however, regulatory guidance from the FDA has evolved in recent years, and the compliance landscape for compounded peptides continues to shift.

Individuals interested in peptides like BPC 157 should be aware that access, legal status, and quality standards vary significantly by jurisdiction and provider. Working with a licensed, knowledgeable healthcare provider who understands the regulatory environment is essential to navigating this space responsibly. The Peptide Association maintains a directory of practitioners who are informed about current compliance requirements and can guide patients through lawful, evidence-informed options.

What Patients Should Know

If you have read about BPC 157 in the context of cardiovascular health, recovery, or vascular function, this study adds a meaningful — though preliminary — layer to that conversation. Here is what it is reasonable to take away from the current evidence:

• The research is promising but early. Human tissue data is more relevant than animal data, but ex vivo studies are not the same as clinical trials. No conclusions about patient outcomes can yet be drawn.
• The mechanism is biologically plausible. Nitric oxide-mediated vasorelaxation is a well-understood physiological process, and identifying that BPC 157 appears to engage it in human tissue gives researchers a credible target for follow-up investigation.
• Self-administration without medical guidance is inadvisable. Given the absence of approved clinical indications and the evolving regulatory environment, patients should consult a qualified healthcare provider before considering any peptide protocol.
• Quality matters. Not all compounded or research-grade peptides are manufactured to the same standards. Sourcing and provider credentials are critical considerations.

This study does not establish BPC 157 as a treatment for any cardiovascular condition, and this article should not be read as an endorsement of its use for that purpose. Rather, it reflects the kind of rigorous, mechanistically grounded research that the Peptide Association believes should underpin any clinical conversation about peptide therapies.

Conclusion

The 2026 study by Yildirim and colleagues represents a meaningful contribution to the scientific understanding of BPC 157's vascular activity. By demonstrating concentration-dependent vasorelaxation in human internal mammary artery tissue — and linking that effect primarily to endothelium-dependent nitric oxide signaling — the research opens a credible avenue for continued investigation into BPC 157's cardiovascular mechanisms.

As with all emerging areas of peptide science, the path from mechanistic discovery to clinical application is long and requires rigorous human trial data. The Peptide Association is committed to tracking and communicating this evidence as it develops.

If you are interested in speaking with a healthcare provider who is knowledgeable about peptide research and current regulatory standards, we encourage you to find a qualified practitioner through our directory at peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content reflects findings from published scientific research and should not be used as a basis for self-diagnosis or self-treatment. Always consult a qualified and licensed healthcare provider before beginning any new health regimen, including the use of peptides or other investigational compounds. The Peptide Association does not endorse any specific treatment or product.

---

Citation: Yildirim AK, Dastan AO, Demeli Ertus M, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. 2026;15(9):3488. doi:10.3390/jcm15093488. PMID: 42123221.